Core Viewpoint - Immunocore Holdings plc will report its financial results for the fourth quarter and full year 2025 on February 25, 2026, and will host a teleconference to discuss these results and provide a business update [1][2]. Company Overview - Immunocore is a commercial-stage biotechnology company focused on developing TCR bispecific immunotherapies, known as ImmTAX, aimed at treating various diseases including cancer, autoimmune diseases, and infectious diseases [4]. - The company has a robust pipeline in multiple therapeutic areas, with both clinical and pre-clinical programs [4]. - Its leading oncology TCR therapeutic, KIMMTRAK, is approved for treating HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in several regions including the US, EU, Canada, Australia, and the UK [4]. Conference Call Details - The live teleconference will take place at 8:00 a.m. EST (1:00 p.m. GMT) and will be accessible via the company's website [2][3]. - A replay of the event will be available for a limited time after the live call [3]. Contact Information - The company has provided contact details for communications and investor relations, including names, phone numbers, and email addresses for inquiries [5].

Company Overview - Immunocore Holdings plc (NASDAQ:IMCR) is a biotechnology company focused on developing TCR bispecific immunotherapies for cancer, infectious diseases, and autoimmune conditions, utilizing its proprietary ImmTAX technology [4] Investment Potential - Analysts from H.C. Wainwright and UBS have reiterated a Buy rating for Immunocore, with price targets of $100 and $55 respectively, indicating strong confidence in the stock's future performance [1][2] - UBS highlights significant upside potential for the stock, as it is currently trading near the value of its approved drug Kimmtrak, suggesting that the market has not fully valued the company's upcoming phase 3 trials [2] Upcoming Trials - The company has two key upcoming trials: the TEBE-AM trial for second-line Kimmtrak in metastatic cutaneous melanoma, with data expected by late 2026 or early 2027, and the first-line PRAME trial, with data anticipated in late 2027 or 2028 [3] Market Impact - Positive results from the upcoming trials could potentially boost the stock by 25% to 50% and contribute an additional $300 million to $400 million in annual sales [2]

Core Insights - Immunocore Holdings plc announces the departure of Dr. David Berman, Executive Vice President of Research and Development, effective February 27, 2026, as he takes a new role at another biotech company [1] - The company will not seek a direct replacement for Dr. Berman but will streamline its R&D structure, promoting Dr. Mohammed Dar and Mark Moyer to Executive Vice President roles [2] Leadership Changes - Dr. Mohammed Dar, previously Chief Medical Officer, has extensive experience in leading clinical development and will now oversee expanded clinical development and regulatory strategies [4] - Mark Moyer, who has been with Immunocore since 2018, will become EVP, Chief Regulatory and Quality Officer, having led the regulatory strategy for KIMMTRAK, which is now approved in 39 countries [5] Company Overview - Immunocore is a commercial-stage biotechnology company focused on developing TCR bispecific immunotherapies, particularly its lead product KIMMTRAK, which treats HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma [6]

Core Viewpoint - Immunocore Holdings plc is set to report its second quarter financial results on August 7, 2025, and will host a teleconference to discuss these results and provide a business update [1][2]. Company Overview - Immunocore is a commercial-stage biotechnology company focused on developing TCR bispecific immunotherapies, known as ImmTAX, aimed at treating various diseases including cancer, autoimmune diseases, and infectious diseases [4]. - The company's leading oncology product, KIMMTRAK, is approved for treating HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in multiple regions including the US, EU, Canada, Australia, and the UK [4]. Upcoming Events - A live teleconference and webcast will occur on August 7, 2025, at 8:00 a.m. EDT to discuss the financial results and provide updates on the business and portfolio [2][3]. Contact Information - For inquiries, Immunocore's VP of Communications is Sébastien Desprez, reachable at +44 (0) 7458030732 or via email at sebastien.desprez@immunocore.com [7]. - Investor relations can be contacted through Clayton Robertson or Morgan Warenius at +1 (215) 384-4781 or ir@immunocore.com [7].

Core Insights - Immunocore Holdings plc is a commercial-stage biotechnology company focused on developing immunomodulating medicines for cancer, infectious diseases, and autoimmune diseases [1][3] - The company will participate in the 2025 Jefferies Global Healthcare Conference, indicating its ongoing engagement with investors and the healthcare community [1][2] Company Overview - Immunocore is pioneering a novel class of TCR bispecific immunotherapies known as ImmTAX, aimed at treating a wide range of diseases [3] - The company has a robust pipeline with multiple active clinical and pre-clinical programs across oncology, infectious diseases, and autoimmune diseases [3] - KIMMTRAK, Immunocore's leading oncology TCR therapeutic, is approved for treating HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in several regions including the US, EU, Canada, Australia, and the UK [3]